Dr. Feigin is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
222 E 41st St
Fl 13
New York, NY 10017Phone+1 212-263-4838
Education & Training
University of RochesterResidency, Neurology, 1989 - 1992
New York Presbyterian Hospital (Columbia Campus)Internship, Internal Medicine, 1988 - 1989
Columbia University Vagelos College of Physicians and SurgeonsClass of 1988
Certifications & Licensure
FL State Medical License 2021 - Present
NY State Medical License 1992 - 2025- American Board of Psychiatry and Neurology Neurology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification Allscripts Enterprise EHR, Allscripts, 2013
Clinical Trials
- Creatine Safety, Tolerability, & Efficacy in Huntington's Disease (CREST-E) Start of enrollment: 2009 Sep 01
Publications & Presentations
PubMed
- 408 citationsAAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trialPeter A. LeWitt, Ali R. Rezai, Maureen A. Leehey, Steven G. Ojemann, Alice W. Flaherty
The Lancet. Neurology. 2011-04-01 - 48 citationsRasagiline improves quality of life in patients with early Parkinson's diseaseKevin M. Biglan, Steven R. Schwid, Shirley Eberly, Karen Blindauer, S. Fahn
Movement Disorders. 2006-05-01 - 130 citationsA double-blind, placebo-controlled trial of intravenous iron dextran therapy in patients with ESRD and restless legs syndrome.James A. Sloand, Mark Shelly, Andrew Feigin, Paul Bernstein, Rebeca D. Monk
American Journal of Kidney Diseases. 2004-04-01
Press Mentions
AAN 2023: Pridopidine Phase 3 Trial Misses Goal, but Benefits Seen for SomeMay 2nd, 2023- Prilenia Shares Preliminary Topline Results from Phase 3 PROOF-HD Clinical Trial in Huntington's Disease and Data from Phase 2 HEALEY ALS Platform Trial of Pridopidine at the 75th American Academy of Neurology (AAN) Annual MeetingApril 25th, 2023
- Parkinson’s Cases May Be 50% Higher Than Previously Thought: Why That’s Important to KnowDecember 15th, 2022
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
